|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5521288A
(en)
|
1990-03-26 |
1996-05-28 |
Bristol-Myers Squibb Company |
CD28IG fusion protein
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
ES2206446T3
(es)
|
1991-05-06 |
2004-05-16 |
The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services |
Virus recombinante que expresa un antigeno carcinoembrionico y metodos de uso del mismo.
|
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
US5942607A
(en)
|
1993-07-26 |
1999-08-24 |
Dana-Farber Cancer Institute |
B7-2: a CTLA4/CD28 ligand
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
JP4418965B2
(ja)
|
1994-09-23 |
2010-02-24 |
タップイミューン・インコーポレイテッド |
内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法
|
|
EP1016418B1
(en)
|
1994-10-03 |
2009-12-30 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
AU715543B2
(en)
|
1995-09-08 |
2000-02-03 |
Genzyme Corporation |
Improved AAV vectors for gene therapy
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
EP1012275A1
(en)
|
1997-01-31 |
2000-06-28 |
University Of Rochester |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6730512B2
(en)
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
IL132560A0
(en)
|
1997-05-02 |
2001-03-19 |
Genentech Inc |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
EP1012236A1
(en)
|
1997-08-15 |
2000-06-28 |
Rubicon Laboratory Inc. |
Retrovirus and viral vectors
|
|
JP2001517454A
(ja)
|
1997-09-19 |
2001-10-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
KR20010085348A
(ko)
|
1998-08-07 |
2001-09-07 |
추후보정 |
면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법
|
|
JP2002538770A
(ja)
|
1998-11-10 |
2002-11-19 |
ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
ウイルスベクターとその製造及び投与の方法
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL220113B1
(pl)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
AU779395B2
(en)
|
1999-04-30 |
2005-01-20 |
Institut De Recherche Cliniques De Montreal (Ircm) |
Mutant human CD80 and compositions for and methods of making and using the same
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
CA2379166C
(en)
|
1999-08-09 |
2013-03-26 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
AU2584901A
(en)
|
1999-12-22 |
2001-07-03 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
BRPI0107736B8
(pt)
|
2000-01-21 |
2021-05-25 |
Biovex Ltd |
cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
AU2001272978A1
(en)
|
2000-06-23 |
2002-01-08 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
|
WO2004029197A2
(en)
*
|
2001-06-22 |
2004-04-08 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
NZ522844A
(en)
|
2000-06-28 |
2005-02-25 |
Brigham & Womens Hospital |
PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
|
|
SI1372696T1
(sl)
|
2000-07-03 |
2008-12-31 |
Bristol Myers Squibb Co |
Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
GB0021976D0
(en)
|
2000-09-07 |
2000-10-25 |
Optomed As |
Multi-parameter fiber optic probes
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
WO2002091997A2
(en)
|
2001-05-11 |
2002-11-21 |
Pro-Virus, Inc. |
Oncolytic virus therapy
|
|
US20030044386A1
(en)
|
2001-07-11 |
2003-03-06 |
Barber Glen N. |
Recombinant VSV for the treatment of tumor cells
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
AU2002352913B2
(en)
|
2001-11-30 |
2008-05-29 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Peptide agonists of prostate-specific antigen, and uses therefor
|
|
US20040009604A1
(en)
|
2002-03-27 |
2004-01-15 |
Xiaoliu Zhang |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
EP1539230A4
(en)
|
2002-06-21 |
2007-10-31 |
Wellstat Biologics Corp |
ADMINISTRATION OF THERAPEUTIC VIRUSES
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
AU2003268505A1
(en)
|
2002-09-09 |
2004-03-29 |
University Of Tennessee Research Foundation |
Recombinatant mutants of rhabdovirus and methods of use thereof
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
EP1944320A1
(en)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
ES2319424T3
(es)
|
2003-03-27 |
2009-05-07 |
Ottawa Health Research Institute |
Virus mutantes de la estomatitis vesivular y sus usos.
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
MXPA05013879A
(es)
|
2003-06-18 |
2006-06-27 |
Genelux Corp |
Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
|
|
EP3910063A1
(en)
|
2003-09-30 |
2021-11-17 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
US20070003520A1
(en)
|
2003-11-17 |
2007-01-04 |
Brown Susanne M |
Mutant viruses
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
DK1718677T3
(da)
|
2003-12-19 |
2012-07-09 |
Genentech Inc |
Monovalente antistoffragmenter egnede som terapeutiske midler
|
|
EP2374817B1
(en)
|
2004-04-13 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Anti-P-selectin antibodies
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
JP2008505174A
(ja)
|
2004-07-15 |
2008-02-21 |
ゼンコー・インコーポレイテッド |
最適化Ｆｃ変異体
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
CA2580981C
(en)
|
2004-09-22 |
2013-10-22 |
Kirin Beer Kabushiki Kaisha |
Stabilized human igg4 antibodies
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
EP3623473A1
(en)
|
2005-03-31 |
2020-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
AU2006252406B2
(en)
|
2005-06-01 |
2012-05-17 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
|
CN101495126B
(zh)
|
2005-06-23 |
2016-01-06 |
休斯顿大学 |
Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
DK2048955T3
(da)
|
2006-07-21 |
2013-09-02 |
California Inst Of Techn |
Målrettet gen-tilførsel til dendrit-cellevaccination
|
|
US8052968B2
(en)
|
2006-10-16 |
2011-11-08 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
EP2114420B1
(en)
|
2007-02-16 |
2016-01-27 |
Virttu Biologics Limited |
Herpes simplex viruses and methods of viral replication
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
JP5213075B2
(ja)
|
2007-06-15 |
2013-06-19 |
ジェネラックス・コーポレイション |
腫瘍の画像化および／または処置のための微生物
|
|
US8153595B2
(en)
|
2007-07-13 |
2012-04-10 |
The Johns Hopkins University |
B7-DC variants immunogenic compositions and methods of use thereof
|
|
JP2010533718A
(ja)
|
2007-07-18 |
2010-10-28 |
ジェネラックス・コーポレイション |
腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
CN103172750B
(zh)
|
2007-11-01 |
2014-12-10 |
安斯泰来制药有限公司 |
免疫抑制性多肽与核酸
|
|
WO2009067800A1
(en)
|
2007-11-27 |
2009-06-04 |
Viventia Biotech Inc. |
Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof
|
|
LT2222861T
(lt)
|
2007-12-11 |
2018-03-26 |
The University Of North Carolina At Chapel Hill |
Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
KR101855381B1
(ko)
|
2008-04-09 |
2018-05-09 |
제넨테크, 인크. |
면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
|
|
US20120052003A9
(en)
|
2008-05-16 |
2012-03-01 |
Szalay Aladar A |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
US20110159023A1
(en)
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
|
EP3936122A1
(en)
|
2008-11-24 |
2022-01-12 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
WO2010080909A1
(en)
|
2009-01-08 |
2010-07-15 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
AU2010276194B2
(en)
|
2009-07-24 |
2012-02-02 |
Immune Design Corp |
Lentiviral vectors pseudotyped with a Sindbis virus envelope glycoprotein
|
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
JP5960597B2
(ja)
|
2009-09-30 |
2016-08-02 |
メモリアル スローン−ケタリング キャンサー センター |
癌治療のための併用免疫療法
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012125850A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Fc variants
|
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
SMT201700025T1
(it)
|
2011-04-13 |
2017-03-08 |
Bristol Myers Squibb Co |
Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
US8609625B2
(en)
|
2011-06-24 |
2013-12-17 |
Taipei Veterans General Hospital |
Method for enhancing immune response in the treatment of infectious and malignant diseases
|
|
PL2726101T3
(pl)
|
2011-06-30 |
2019-01-31 |
Genzyme Corporation |
Inhibitory aktywacji komórek t
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
MX366864B
(es)
|
2012-02-27 |
2019-07-26 |
Amunix Operating Inc |
Composiciones de conjugados de xten y métodos para realizarlas.
|
|
CA2868838C
(en)
|
2012-03-30 |
2022-07-05 |
Immune Design Corp. |
Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
|
|
WO2013169338A1
(en)
|
2012-05-11 |
2013-11-14 |
Medimmune, Llc |
Ctla-4 variants
|
|
WO2013184912A2
(en)
|
2012-06-06 |
2013-12-12 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the hippo pathway and uses thereof
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
CA2892831A1
(en)
|
2012-12-04 |
2014-06-12 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US20160017041A1
(en)
|
2013-03-15 |
2016-01-21 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
EP3789036A1
(en)
|
2013-07-16 |
2021-03-10 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
CN110903398B
(zh)
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
EP3105333B1
(en)
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
AU2015289773A1
(en)
|
2014-07-15 |
2017-02-02 |
Immune Design Corp. |
Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector
|
|
CR20170014A
(es)
|
2014-07-16 |
2017-10-17 |
Hoffmann La Roche |
Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
|
|
PT3177640T
(pt)
|
2014-08-08 |
2020-08-31 |
Univ Leland Stanford Junior |
Agentes pd-1 de alta afinidade e métodos de utilização
|
|
KR20160021586A
(ko)
|
2014-08-18 |
2016-02-26 |
지경민 |
시력교정용 필터 및 이를 이용한 시력교정방법
|
|
US10576141B2
(en)
|
2014-09-03 |
2020-03-03 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
|
|
EP3215539A4
(en)
|
2014-11-06 |
2018-05-23 |
Children's Research Institute, Children's National |
Immunotherapeutics for cancer and autoimmune diseases
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
AU2016240411A1
(en)
|
2015-04-02 |
2017-10-12 |
Cancure Limited |
Agents and compositions for eliciting an immune response
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
SI3283508T1
(sl)
|
2015-04-17 |
2021-09-30 |
Alpine Immune Sciences, Inc. |
Imunomodulirajoči proteini z nastavljivimi afinitetami
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
HUE061253T2
(hu)
|
2015-05-29 |
2023-06-28 |
Bristol Myers Squibb Co |
Antitestek OX40 ellen és azok felhasználásai
|
|
SMT202100527T1
(it)
|
2015-07-30 |
2021-11-12 |
Macrogenics Inc |
Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
|
|
WO2017023779A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
US20180221508A1
(en)
|
2015-07-31 |
2018-08-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
CA2995462A1
(en)
|
2015-08-12 |
2017-02-16 |
First Quality Packaging Solutions, Llc |
Container and method of forming the same
|
|
EP3337496B1
(en)
|
2015-08-20 |
2020-11-25 |
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. |
B7-h1 fusion polypeptides for use in treating and preventing organ failure
|
|
JP2018534245A
(ja)
|
2015-09-14 |
2018-11-22 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法
|
|
DK3368572T3
(da)
|
2015-10-02 |
2022-08-08 |
Symphogen As |
Anti-pd-1-antistoffer og -sammensætninger
|
|
PE20181300A1
(es)
|
2015-11-02 |
2018-08-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
|
|
JP2019516665A
(ja)
|
2016-03-02 |
2019-06-20 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
SG11201808457PA
(en)
|
2016-04-15 |
2018-10-30 |
Alpine Immune Sciences Inc |
Icos ligand variant immunomodulatory proteins and uses thereof
|
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
US11505591B2
(en)
|
2016-05-18 |
2022-11-22 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR20190044029A
(ko)
|
2016-05-18 |
2019-04-29 |
알버트 아인슈타인 컬리지 오브 메디슨, 인크. |
변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
PE20240950A1
(es)
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
CA3053812A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
|
WO2018170026A2
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
LT3596116T
(lt)
|
2017-03-16 |
2023-11-10 |
Alpine Immune Sciences, Inc. |
Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
|
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
SG11202102644XA
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences Inc |
Methods and uses of variant cd80 fusion proteins and related constructs
|